Brokerages Set Aligos Therapeutics, Inc. (NASDAQ:ALGS) Target Price at $38.50

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $38.50.

A number of analysts have recently weighed in on the company. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. Wall Street Zen raised Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Sunday, May 17th. Lake Street Capital began coverage on Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 price target for the company. Weiss Ratings downgraded Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. Finally, HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research note on Wednesday, March 11th.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently bought and sold shares of ALGS. Bank of America Corp DE grew its position in Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after purchasing an additional 216,646 shares during the last quarter. SummitTX Capital L.P. raised its holdings in shares of Aligos Therapeutics by 6.7% in the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after buying an additional 9,375 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Aligos Therapeutics by 17.6% during the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock worth $746,000 after buying an additional 15,006 shares during the period. Rockefeller Capital Management L.P. lifted its stake in shares of Aligos Therapeutics by 900.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of Aligos Therapeutics during the fourth quarter valued at $215,000. 60.43% of the stock is currently owned by institutional investors and hedge funds.

Aligos Therapeutics Stock Performance

NASDAQ:ALGS opened at $6.73 on Friday. The company’s 50-day simple moving average is $5.67 and its 200-day simple moving average is $7.06. Aligos Therapeutics has a fifty-two week low of $4.80 and a fifty-two week high of $13.69. The stock has a market capitalization of $41.66 million, a P/E ratio of -0.77 and a beta of 2.26.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($2.21) EPS for the quarter, topping the consensus estimate of ($2.29) by $0.08. The firm had revenue of $2.83 million during the quarter, compared to analyst estimates of $0.25 million. Aligos Therapeutics had a negative net margin of 1,919.68% and a negative return on equity of 139.47%. On average, research analysts forecast that Aligos Therapeutics will post -7.47 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.